A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs Anamorelin (Primary)
- Indications Anorexia; Cachexia
- Focus Registrational; Therapeutic Use
- Sponsors Helsinn Healthcare SA
- 07 Mar 2019 According to a Helsinn media release, first patient has now been dosed in the new global Phase III program which consist two studies of identical design ( NCT03743051 & NCT03743064 ).
- 07 Feb 2019 Status changed from not yet recruiting to recruiting.
- 22 Nov 2018 New trial record